CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Perspective Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.19+0.02 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $264.23M
- P/E (TTM)
- –
- Dividend yield
- –
Perspective Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Market Cap | $249.99M | $166.30M |
| Enterprise Value | $14.63M | $88.19M |
| PB Ratio | 0.77 | 2.03 |
| P/TBV Ratio | 0.77 | 2.29 |
Income (trailing twelve months)
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$125.23M | -$21.40M |
| Net Income | -$116.43M | -$22.46M |
| EBITDA | -$121.18M | -$16.91M |
| EPS (Diluted) | -$1.32 | -$0.83 |
Returns
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -39.5% | -53.2% |
| Return on Assets (ROA) | -33.1% | -40.9% |
| Return on Invested Capital (ROIC) | -120.5% | -32.4% |
| Return on Capital Employed (ROCE) | -35.2% | -38.1% |
Balance sheet
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $236.90M | $61.43M |
| Total Debt | $1.54M | $118.52M |
| Net Cash (Debt) | $235.36M | $15.35M |
| Net Cash Per Share | $2.06 | $0.66 |
| Equity (Book Value) | $323.86M | $49.09M |
| Book Value Per Share | $2.84 | $1.37 |
| Tangible Book Value | $323.86M | $23.52M |
| Working Capital | $204.98M | $76.81M |
Financial position
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.61 | 3.34 |
| Quick Ratio | 6.49 | 2.44 |
| Debt / Equity | 0.00 | 0.52 |
Cash flow (trailing twelve months)
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$93.07M | -$12.35M |
| Capital Expenditures | -$28.12M | -$1.08M |
| Free Cash Flow | -$121.19M | -$20.22M |
| FCF Per Share | -$1.06 | -$0.42 |
Efficiency
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$701.41K | -$703.34K |
| Employee Count | 166 | 74 |
Dividends and yields
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -46.6% | -23.3% |
| FCF Yield | -48.5% | -8.72% |
Shares
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 114,152,000 | 58,127,000 |
| Shares Change (YoY) | 29.5% | 10.9% |
| Shares Change (QoQ) | 0.06% | 0.54% |
| Float | 103,550,000 | 49,136,700 |
| Shares Held by Insiders | 9.29% | 11.6% |
| Shares Held by Institutions | 78.2% | 59.4% |
Scores
| Measure | Perspective Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 0.39 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Perspective Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.